When 24-year-old Charles Dougherty checks into Vanderbilt-Ingram Cancer Center tomorrow, he'll be preparing for a treatment that has never been performed before in an adult patient in Nashville, and will be only the second case in Tennessee history.

Initial Results of the Study of Tamoxifen and Raloxifene or STAR, released today revealed the osteoporosis drug raloxifene has been proved to be as effective as tamoxifen in preventing invasive breast cancer.

Researchers at the Vanderbilt-Ingram Cancer Center are studying whether exercise can help curb memory and cognitive problems experienced by many cancer survivors following chemotherapy.

Ginseng, one of the most widely used herbs in traditional Chinese medicine, may improve survival and quality of life after a diagnosis of breast cancer, according to a recent study by Vanderbilt-Ingram Cancer Center researchers. The large epidemiological study, led by Xiao-Ou Shu, M.D., Ph.D., was published online recently in the American Journal of Epidemiology.

A team of researchers at Vanderbilt-Ingram Cancer Center has been awarded $1.5 million from the Susan G. Komen Breast Cancer Foundation.

Can the high doses of chemotherapy and radiation that young cancer patients receive cause inherited health problems for their children?

Thanks to Vanderbilt-Ingram Cancer Center's new Clinical Trials Mentor Program, patients considering enrolling in a clinical trial can now ask questions and get first-hand accounts from patient advocates who have already gone through the process.